COVID-19 has forced Life Sciences manufacturers to rethink trial timelines and speed up vaccine and drug development, without compromising on safety and quality. Life Sciences manufacturers must be equipped with technology and processes that not only automate core budgeting, contracting and forecasting processes, but also enable business agility and accelerate execution of these study startup activities.